GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2026 financial results after market close on Monday, November 9, 2026.
GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences. Details on the Company’s participation appear below:
Cramer recommends buying Carpenter Technology (NYSE: CRS) and calls DXC Technology (NYSE: DXC) a value trap. Senseonics Holdings (NASDAQ: SENS) posts upbeat sales and Ubiquiti (NYSE: UI) reports worse-than-expected results. Hess Midstream (NYSE: HESM) is a winner while Zeta Global (NYSE: ZETA) announces a new CMO. UL Solutions (NYSE: ULS) is a potential buy and Coupang (NYSE: CPNG) is not recommended, but MercadoLibre (NASDAQ: MELI) and Amazon (NASDAQ: AMZN) are worth considering.
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
Net revenue for the second quarter totaled $14.5 million, compared with $
GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced second quarter 2026 financial results and provided a business update.
